Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Congenital Heart Disease (CHD) Market Over the Forecast Period of 2025 to 2034?

In recent times, there has been a swift expansion in the congenital heart disease (CHD) market. It is projected to inflate from $4.42 billion in 2024 to about $4.87 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The surge during the historic period is influenced by several factors including the rising incidences of risk factors such as obesity and smoking, advancements in diagnostic technology, growing elderly population, amplified awareness campaigns, improved reimbursement procedures, as well as amplified funding in research and development.

Anticipated to witness significant growth in the near future, the market size of congenital heart disease (CHD) is predicted to escalate to $7.05 billion by the year 2029, maintaining a compound annual growth rate (CAGR) of 9.7%. This rising trend during the forecasted period is ascribed to the increasing availability of healthcare amenities in the emerging regions, ongoing advancements in cardiac imaging technology, enhanced emphasis on early detection and solution via awareness campaigns, heightened global healthcare spending, and the evolution of individualized medicine. Dominant patterns during this period involve the incorporation of minimally invasive surgical procedures, extended use of telemedicine for distant patient monitoring and consultations, growing requirement for tailored treatment methods, the production of pioneering implantable apparatus featuring improved performance and durability, along with the integration of artificial intelligence and machine learning into diagnostic and therapeutic procedures.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Congenital Heart Disease (CHD) Market?

The surge in instances of maternal diabetes is predicted to spur the growth of the congenital heart disease (CHD) market in the future. Maternal diabetes, known as gestational diabetes mellitus (GDM), is defined as the emergence of diabetes in females during pregnancy who were not previously diabetic. The reasons for maternal diabetes are modifications in lifestyle such as lack of physical activity, unhealthy eating patterns, and the overall increase in obesity amongst reproductive-age women. Maternal diabetes can predispose infants to congenital heart disease (CHD) due to high blood sugar levels impacting the heart’s development during fetal stages. This elevated glucose level in a pregnant woman’s blood can adversely affect the normal growth of an infant’s heart, leading to a higher probability of CHD. For example, the National Health Service, a government department in the UK, reported in October 2023 that the adverse pregnancy outcomes increased from 4.9% in 2021 to 6.6% in 2022 amongst women diagnosed with type 2 diabetes. Consequently, the surge in maternal diabetes cases is fuelling the growth of the congenital heart disease (CHD) market.

Request Your Free Congenital Heart Disease (CHD) Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (CHD) market are:

• Pfizer Inc.

• AstraZeneca Plc

• Abbott Laboratories

• Novartis AG

• Medtronic

What Key Trends Are Currently Impacting the Congenital Heart Disease (CHD) Market’s Development?

Key players in the congenital heart disease marketplace are advancing towards the creation of non-surgical heart valves with the aim of enhancing both patient outcomes and life quality. These non-surgical or transcatheter heart valves are healthcare apparatuses that serve to manage heart valve illnesses without the necessity for conventional open-heart operations. For instance, in February 2023, Medtronic, an American medical tech firm, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System. This innovative, minimally invasive option provides an alternative to open-heart surgery for congenital heart disease patients, particularly those with inherent or surgically corrected right ventricular outflow tract (RVOT) irregularities. The System, which is the first FDA-approved valve specifically designed for the right side, offers a non-surgical remedy for severe pulmonary valve regurgitation patients. In 2021, the Harmony TPV System acquired approval from the U.S FDA. Its reintroduction after a voluntary recall is demonstrative of Medtronic’s dedication to progressing solutions for those suffering from congenital heart disease.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Key Segments Define the Structure of the Congenital Heart Disease (CHD) Market and Their Growth Potential?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Geographical Regions Are Pioneering Growth in the Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Congenital Heart Disease (CHD) Market Landscape?

Congenital heart disease (CHD) refers to a range of birth defects affecting the structure and function of the heart that are present at birth. These defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. The treatment for CHD depends on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Digital Solutions Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Ultrasound Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: